| pubmed-article:3918109 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3918109 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:3918109 | lifeskim:mentions | umls-concept:C0031307 | lld:lifeskim |
| pubmed-article:3918109 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:3918109 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:3918109 | lifeskim:mentions | umls-concept:C0162524 | lld:lifeskim |
| pubmed-article:3918109 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:3918109 | pubmed:dateCreated | 1985-3-20 | lld:pubmed |
| pubmed-article:3918109 | pubmed:abstractText | Anti-My-26, a mouse monoclonal IgG1 antibody, was raised against human granulocytes and has been shown to inhibit luminol-enhanced, glucose-independent chemiluminescence (CL) of human granulocytes (or monocytes) responding to the soluble secretagogues A23187 or ionomycin (calcium ionophores) and phorbol myristate acetate (PMA). Anti-My-26 inhibition of CL was reversible and was dependent on both secretatogue and monoclonal antibody concentration. This inhibition appeared to be directed at the component of granulocyte CL that is independent of NAD(P)H-oxidase-catalyzed formation of superoxide anion, because neither opsonized zymosan-stimulated CL nor the PMA-induced decrease in NAD (P)H-associated autofluorescence was affected by anti-My-26. In addition, ionomycin, over a wide concentration range, failed to generate any decrease in granulocyte autofluorescence. The A23187-induced CL inhibited by anti-My-26 was correlated with its depression of oxygen consumption. Furthermore, anti-My-26 was not cytotoxic and did not itself induce oxidative metabolism when used as a stimulant. Binding of anti-My-26 to phagocytic cells was not decreased by pre-exposure of cells to either A23187 or PMA. Evidence is presented to suggest that the binding of anti-My-26 to the granulocyte surface inhibits the oxidative response to calcium ionophore and PMA by blocking a common pathway(s) stimulated by these different secretagogues. | lld:pubmed |
| pubmed-article:3918109 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3918109 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3918109 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3918109 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3918109 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:3918109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3918109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3918109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3918109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3918109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3918109 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3918109 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:3918109 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:3918109 | pubmed:author | pubmed-author:WarrenJ TJT | lld:pubmed |
| pubmed-article:3918109 | pubmed:author | pubmed-author:CivinC ICI | lld:pubmed |
| pubmed-article:3918109 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3918109 | pubmed:volume | 134 | lld:pubmed |
| pubmed-article:3918109 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3918109 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3918109 | pubmed:pagination | 1827-35 | lld:pubmed |
| pubmed-article:3918109 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:meshHeading | pubmed-meshheading:3918109-... | lld:pubmed |
| pubmed-article:3918109 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:3918109 | pubmed:articleTitle | Anti-My-26: a monoclonal antibody inhibiting human phagocyte chemiluminescence. | lld:pubmed |
| pubmed-article:3918109 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3918109 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:3918109 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3918109 | lld:pubmed |
